These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 24021289

  • 1. Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients.
    Tanaka H, Arai M, Tomoda Y, Wada T, Yago K, Satoh M.
    J Pharm Pharm Sci; 2013; 16(3):405-13. PubMed ID: 24021289
    [Abstract] [Full Text] [Related]

  • 2. Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
    Gianotti N, Galli L, Poli A, Salpietro S, Nozza S, Carbone A, Merli M, Ripa M, Lazzarin A, Castagna A.
    Medicine (Baltimore); 2016 May; 95(22):e3780. PubMed ID: 27258510
    [Abstract] [Full Text] [Related]

  • 3. Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.
    Cao Y, Han Y, Xie J, Cui Q, Zhang L, Li Y, Li Y, Song X, Zhu T, Li T.
    BMC Infect Dis; 2013 Jul 01; 13():301. PubMed ID: 23815472
    [Abstract] [Full Text] [Related]

  • 4. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, Tian M, Fredrick LM, Podsadecki TJ, Nilius AM.
    HIV Clin Trials; 2011 Jul 01; 12(5):255-67. PubMed ID: 22180523
    [Abstract] [Full Text] [Related]

  • 5. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
    Piketty C, Gérard L, Chazallon C, Marcelin AG, Clavel F, Taburet AM, Calvez V, Madelaine-Chambrin I, Molina JM, Aboulker JP, Girard PM, Agence Nationale de Recherche sur le SIDA 107-Puzzle 2 Study Group.
    Antivir Ther; 2006 Jul 01; 11(2):213-21. PubMed ID: 16640102
    [Abstract] [Full Text] [Related]

  • 6. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
    Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T, Yang O, Dubé MP, Murphy RL, Stein JH, McComsey GA.
    J Infect Dis; 2015 Oct 15; 212(8):1241-9. PubMed ID: 25948863
    [Abstract] [Full Text] [Related]

  • 7. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
    Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R, Louie S, California Collaborative Treatment Group 578 Team.
    J Infect Dis; 2008 Jan 01; 197(1):102-8. PubMed ID: 18171292
    [Abstract] [Full Text] [Related]

  • 8. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
    Gallant JE, Koenig E, Andrade-Villanueva J, Chetchotisakd P, DeJesus E, Antunes F, Arastéh K, Moyle G, Rizzardini G, Fehr J, Liu Y, Zhong L, Callebaut C, Szwarcberg J, Rhee MS, Cheng AK.
    J Infect Dis; 2013 Jul 01; 208(1):32-9. PubMed ID: 23532097
    [Abstract] [Full Text] [Related]

  • 9. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
    Young J, Schäfer J, Fux CA, Furrer H, Bernasconi E, Vernazza P, Calmy A, Cavassini M, Weber R, Battegay M, Bucher HC, Swiss HIV Cohort Study.
    AIDS; 2012 Mar 13; 26(5):567-75. PubMed ID: 22398568
    [Abstract] [Full Text] [Related]

  • 10. Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
    Gérard L, Chazallon C, Taburet AM, Girard PM, Aboulker JP, Piketty C.
    Antivir Ther; 2007 Mar 13; 12(1):31-9. PubMed ID: 17503745
    [Abstract] [Full Text] [Related]

  • 11. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.
    Kulkarni R, Abram ME, McColl DJ, Barnes T, Fordyce MW, Szwarcberg J, Cheng AK, Miller MD, White KL.
    HIV Clin Trials; 2014 Mar 13; 15(5):218-30. PubMed ID: 25350960
    [Abstract] [Full Text] [Related]

  • 12. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
    McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, Myers L, Melbourne K, Ha B, Sax PE.
    J Infect Dis; 2011 Jun 15; 203(12):1791-801. PubMed ID: 21606537
    [Abstract] [Full Text] [Related]

  • 13. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
    Kozal MJ, Lupo S, DeJesus E, Molina JM, McDonald C, Raffi F, Benetucci J, Mancini M, Yang R, Wirtz V, Percival L, Zhang J, Zhu L, Arikan D, Farajallah A, Nguyen BY, Leavitt R, McGrath D, Lataillade M, The Spartan Study Team.
    HIV Clin Trials; 2012 Jun 15; 13(3):119-30. PubMed ID: 22592092
    [Abstract] [Full Text] [Related]

  • 14. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results.
    Rockstroh JK, DeJesus E, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Plummer A, Abram M, Cheng AK, Fordyce MW, Szwarcberg J, GS-236-0103 Study Team.
    J Acquir Immune Defic Syndr; 2013 Apr 15; 62(5):483-6. PubMed ID: 23337366
    [Abstract] [Full Text] [Related]

  • 15. Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients.
    Huang YS, Chan CK, Tsai MS, Lee KY, Lin SW, Chang SY, Hung CC, Chang SC.
    J Microbiol Immunol Infect; 2017 Oct 15; 50(5):595-603. PubMed ID: 26514942
    [Abstract] [Full Text] [Related]

  • 16. Renal function with use of a tenofovir-containing initial antiretroviral regimen.
    Gallant JE, Moore RD.
    AIDS; 2009 Sep 24; 23(15):1971-5. PubMed ID: 19696652
    [Abstract] [Full Text] [Related]

  • 17. Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
    Calza L, Trapani F, Salvadori C, Magistrelli E, Manfredi R, Colangeli V, Di Bari MA, Borderi M, Viale P.
    Scand J Infect Dis; 2013 Feb 24; 45(2):147-54. PubMed ID: 22991923
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
    Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS, ACTG A5257 Team.
    Ann Intern Med; 2014 Oct 07; 161(7):461-71. PubMed ID: 25285539
    [Abstract] [Full Text] [Related]

  • 19. A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.
    Albini L, Cesana BM, Motta D, Focà E, Gotti D, Calabresi A, Izzo I, Bellagamba R, Fezza R, Narciso P, Sighinolfi L, Maggi P, Quiros-Roldan E, Manili L, Guaraldi G, Lapadula G, Torti C.
    J Acquir Immune Defic Syndr; 2012 Jan 01; 59(1):18-30. PubMed ID: 21992924
    [Abstract] [Full Text] [Related]

  • 20. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
    Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R.
    AIDS; 2005 Apr 29; 19(7):685-94. PubMed ID: 15821394
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.